Company / R&D per Share
Phathom Pharmaceuticals, Inc. R&D per Share History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.48
FY2025
5-year range
$0.48 / $1.95
FY2021-FY2025
Trend
-44.4%
vs FY2024
Sector context
#176 of 208
Health Care
What the data says
Phathom Pharmaceuticals, Inc.'s r&d per share of $0.48 is lower than 85% of companies in the Health Care sector (FY2025). R&D per Share has declined for 5 consecutive years, from $2.95 in FY2020 to $0.48 in FY2025.
Based on SEC 10-K filings.
0.48 in FY2025 with a 5-year CAGR of -30.5%.
Declined from $1.20 to $0.48 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -36.0%
- 5-Year CAGR
- -30.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 15% in Health CareTop 85% of 208This company $0.48 Sector average $12.19
▼
-96.1% below sector average
Key checks
Key Insights
- Phathom Pharmaceuticals, Inc.'s r&d per share has declined for 5 consecutive years.
- In FY2025, r&d per share decreased 44.4% year-over-year.
- Ranks #176 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -6.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.48 | -44.4% |
| FY2024 | $0.86 | -28.5% |
| FY2023 | $1.20 | -34.1% |
| FY2022 | $1.83 | -6.6% |
| FY2021 | $1.95 | -33.8% |
| FY2020 | $2.95 | +64.8% |
| FY2019 | $1.79 | +54135.0% |
| FY2018 | $0.00 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026